Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29899392 | 1.00 | ADRB2 (0.41) | — | |
| SCHEMBL244917 | 0.97 | — | — | |
| Oxalic Acid SCHEMBL4816262 | 0.82 | P2RX7 (0.41) | — | |
| Acetic Acid SCHEMBL540945 | 0.80 | P2RX7 (0.40) | — | |
| SCHEMBL17275087 | 0.78 | LMNA (0.43) | — | |
| Hydrochloric Acid SCHEMBL35210959 | 0.77 | HRH1 (0.50) | — | |
| Hydrochloric Acid SCHEMBL3888095 | 0.77 | HRH1 (0.50) | — | |
| Maleic Acid SCHEMBL4976034 | 0.77 | KDM4E (0.45) | — | |
| Quinoline SCHEMBL29151531 | 0.77 | ALDH1A1 (0.71) | — | |
| Fumaric Acid SCHEMBL4976045 | 0.77 | KDM4E (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118666814-A | Atorvastatin non-preparation method | 济南鸿湾生物技术有限公司 | 2024-09-20 | — | — | CN | claimed |
| CN-117430591-A | Synthesis method of avanafil | 康普药业股份有限公司 | 2024-01-23 | — | — | CN | claimed |
| CN-116410141-A | Preparation method of avanafil intermediate | 南京艾德凯腾生物医药有限责任公司 | 2023-07-11 | — | — | CN | claimed |
| CN-114890953-A | Preparation method of 2-aminomethyl pyrimidine hydrochloride | 济南宣正药业有限公司 | 2022-08-12 | — | — | CN | claimed |
| CN-108707141-A | The preparation method of avanaphil | 苏州中联化学制药有限公司 | 2018-10-26 | — | — | CN | claimed |
| CN-104059025-B | A kind of intermediate for preparing avanaphil and preparation method thereof | 广州朗圣药业有限公司 | 2017-07-04 | — | — | CN | claimed |
| CN-105924402-A | Preparation method of 2-amido methylpyrimidine hydrochloride | 蚌埠中实化学技术有限公司 | 2016-09-07 | — | — | CN | claimed |
| WO-2015001567-A1 | PROCESS FOR THE PREPARATION OF (S)-4-[(3-CHLORO-4-METHOXYBENZYL)AMINO]-2-[2- (HYDROXYMETHYL)-1-PYRROLIDINYL]-N-(2-PYRIMIDINYL METHYL-5-PYRIMIDINE CARBOXAMIDE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2015-01-08 | — | — | WO | claimed |
| CN-104059025-A | Novel intermediate used for preparation of avanafil and preparation method thereof | GUANGZHOU REGENEX CORP | 2014-09-24 | — | — | CN | claimed |
| EP-4701737-A2 | MTA-COOPERATIVE PRMT5 INHIBITOR | Pharmaengine, Inc. (TW) | 2026-03-04 | — | — | EP | disclosed |
| US-12459956-B2 | Heterobicyclic carboxamides and uses thereof | ALCON INC. (CH) | 2025-11-04 | — | — | US | disclosed |
| CN-120737077-A | Atorvastatin non-preparation method | 黑龙江乌苏里江制药有限公司 | 2025-10-03 | — | — | CN | disclosed |
| US-12338226-B2 | Substituted benzodiazoles and use thereof in therapy | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2025-06-24 | — | — | US | disclosed |
| WO-2024222914-A2 | MTA-COOPERATIVE PRMT5 INHIBITOR | PHARMAENGINE, INC. (CN) | 2024-10-31 | — | — | WO | disclosed |
| US-7220736-B2 | Pyrimidine compounds | TANABE SEIYAKU CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| EP-1725535-A2 | HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005086700-A2 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20040142930-A1 | Cyclic compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-07-22 | — | — | US | disclosed |
| US-20030229089-A1 | Cyclic compounds | TANABE SEIYAKU CO., LTD. (JP) | 2003-12-11 | — | — | US | disclosed |
| EP-1277741-A1 | CYCLIC COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2003-01-22 | — | — | EP | disclosed |